1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...

Electric building and cap-and-trade program face different kinds of pauses amid legal battles and concern over grid reliability Gov. Kathy Hochul is delaying some elements of her clean energy agenda ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

A new white paper from DISCO found in-house teams are under greater pressure than law firms to adopt gen AI. In-house teams are also more likely to implement gen AI for cost savings, while firms seek ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Microsoft are introducing a new feature to its analytics platform, Benchmarks, that will allow managers to monitor and track AI use amongst their teams. The tool will also allow external comparison in ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Section 1. Background. On July 22, 2025, I announced a framework agreement between the United States and Japan (Agreement), which lays the foundation for a new era of United States-Japan trade ...

Traditional data warehouses—once the backbone of business intelligence and reporting—are increasingly misaligned with today’s data demands. The surge in data volume, velocity and variety has exposed ...